ProVac计划与不断发展的决策支持 - Suppr | 超能文献

The ProVac initiative and evolving decision support.

作者信息

Sanderson Colin F B

机构信息

London School of Hygiene & Tropical Medicine, London, UK.

出版信息

Vaccine. 2015 May 7;33 Suppl 1:A8-10. doi: 10.1016/j.vaccine.2014.12.049.

DOI:10.1016/j.vaccine.2014.12.049

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

The ProVac initiative and evolving decision support.ProVac计划与不断发展的决策支持

Vaccine. 2015 May 7;33 Suppl 1:A8-10. doi: 10.1016/j.vaccine.2014.12.049.

2

Foreword.前言。

Vaccine. 2015 May 7;33 Suppl 1:A1. doi: 10.1016/j.vaccine.2015.02.001.

3

Perspectives on the development and use of economic evidence for immunization decision-making in a developing country.发展中国家免疫接种决策中经济证据的开发与应用展望

Vaccine. 2015 May 7;33 Suppl 1:A6-7. doi: 10.1016/j.vaccine.2014.12.048.

4

Gavi's balancing act: Accelerating access to vaccines while ensuring robust national decision-making for sustainable programmes.全球疫苗免疫联盟的平衡之举：加速疫苗获取，同时确保国家为可持续项目做出有力决策。

Vaccine. 2015 May 7;33 Suppl 1:A4-5. doi: 10.1016/j.vaccine.2014.12.051.

5

Perspectives on expanding the evidence base to inform vaccine introduction: Program costing and cost-effectiveness analyses.关于扩大证据基础以指导疫苗引入的观点：项目成本核算与成本效益分析。

Vaccine. 2015 May 7;33 Suppl 1:A2-3. doi: 10.1016/j.vaccine.2015.01.001.

6

ProVac Global Initiative: a vision shaped by ten years of supporting evidence-based policy decisions.全球ProVac倡议：由十年支持基于证据的政策决策所塑造的愿景。

Vaccine. 2015 May 7;33 Suppl 1:A21-7. doi: 10.1016/j.vaccine.2014.12.080.

7

Strengthening national decision-making on immunization by building capacity for economic evaluation: Implementing ProVac in Europe.通过建设经济评估能力加强国家免疫决策：在欧洲实施ProVac项目

Vaccine. 2015 May 7;33 Suppl 1:A34-9. doi: 10.1016/j.vaccine.2014.12.073.

8

Evidence-based decision-making for vaccine introductions: Overview of the ProVac International Working Group's experience.疫苗引入的循证决策：ProVac国际工作组经验概述

Vaccine. 2015 May 7;33 Suppl 1(0 1):A28-33. doi: 10.1016/j.vaccine.2014.10.090.

9

Valuing vaccines: deficiencies and remedies.重视疫苗：缺陷与补救措施

Vaccine. 2015 Jun 8;33 Suppl 2:B29-33. doi: 10.1016/j.vaccine.2015.03.023.

10

What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?我们从全球疫苗免疫联盟（GAVI）资助国家的综合性多年计划中学到了关于常规免疫接种成本和融资的哪些内容？

Vaccine. 2015 May 7;33 Suppl 1:A93-8. doi: 10.1016/j.vaccine.2014.12.076.

引用本文的文献

1

Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries.预防小儿呼吸道合胞病毒病的药物策略的成本效益：用于低收入和中等收入国家的决策支持模型。

BMC Med. 2023 Apr 11;21(1):138. doi: 10.1186/s12916-023-02827-5.

2

Key Factors Influencing Use of Immunization Cost Evidence in Country Planning and Budgeting Processes: Experiences From Indonesia, Tanzania, and Vietnam.影响免疫规划成本证据在国家规划和预算编制过程中使用的关键因素：来自印度尼西亚、坦桑尼亚和越南的经验。

Glob Health Sci Pract. 2022 Feb 28;10(1). doi: 10.9745/GHSP-D-21-00264.